 BOSTON, Sept. 16, 2021 GLOBE NEWSWIRE -- Aileron Therapeutics Nasdaq: ALRN, a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new clinical data at the European Society of Medical Oncology ESMO Virtual Congress 2021 supporting ALRN-6924s best-in-class potential as a chemoprotective agent. The company presented final results from its completed Phase 1b trial of ALRN-6924 in patients with small cell lung cancer SCLC receiving second-line topotecan treatment, which demonstrated ALRN-6924s triple-play efficacy for the reduction of neutropenia, thrombocytopenia and anemia, as well as a reduction of platelet and red blood cell transfusions, as compared to historical controls. Aileron today also presented preliminary results from its ongoing Phase 1 pharmacology study of ALRN-6924, which confirmed 0.3 mgkg as the optimal dose for ALRN-6924 and confirmed its novel p53 biomarker-driven mechanism of action, as well as its pharmacodynamic effects, including time to onset, magnitude and duration. 